novo nordisk The Danish drugmaker’s CEO said in an interview with CNBC on Wednesday that he is seeking more deals than ever.
“If our goal is to help hundreds of millions of patients, we need not only the best pipeline, but the most extensive pipeline in the world,” said Novo Nordisk CEO Mike Doosder. “So let’s take a look at who else has assets that are basically complementary to what we have. And we’ve been very active in negotiating and acquiring those (business developments) and you’ll continue to see more of that as well.”
Novo created a market for GLP-1 weight loss drugs with weekly doses of Ozempic and Wegovy. The company has recently faced concerns from analysts about whether Novo’s pipeline is robust enough to remain a leader in the increasingly competitive obesity drug field.
Mike Doesder, CEO of Novo Nordisk A/S, during an interview in New York, USA, Wednesday, February 11, 2026.
Michael Nagle | Bloomberg | Getty Images
rival Eli Lilly It has already overtaken Novo in market share for weekly GLP-1 injections, but Novo has an early lead in the new category of GLP-1 pills for weight loss.
Dusdahl said he disagreed with concerns about Novo’s future treatments, arguing that the drug company has “one of the best pipelines in the industry.” He pointed to Novo’s Kaglisema, a drug candidate targeting GLP-1 and amylin that Novo hopes will be approved by the end of this year, and an experimental amylin-targeting drug called Xenagamtide that Novo is accelerating development.
“Of course, there are a lot of things in my pipeline right now that I’m secretly looking into and excited about, but haven’t shared with the world yet,” he said. “So I’m very excited about our pipeline. I would say to investors who are a little bit skeptical, wait and see.”
Dusdahl spoke to CNBC after the company announced that Wigovy tablets’ first-quarter results beat expectations and raised its full-year profit outlook.
